Investigational drug · Phase 2
CP-383
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ).
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CP-383"
First trial start
2025
Aug 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CP-383", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor Malignancies
- Colorectal Carcinoma
- Small Cell Lung Cancer ( SCLC )
- Head and Neck (HNSCC)
- Bladder Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer, Advanced or Metastatic
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Bladder and urothelial cancer · Head and neck cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CP-383" as an intervention, largest first.
Tasca TherapeuticsIndustry
NCT07030257 · 150 participants (planned) · Start Aug 27, 2025 · Primary completion Aug 15, 2028
Drug: CP-383 · For: Solid Tumor Malignancies; Colorectal Carcinoma; Small Cell Lung Cancer ( SCLC ) and 4 more
Sites: Denver, Colorado; Orlando, Florida; Grand Rapids, Michigan · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor Malignancies
- FG-M108M108Phase 32 trials
FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Pancreatic Cancer
- FG-B901Phase 22 trials
FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Solid Tumor
- TYK-01054Phase 21 trial
TYK Medicines, Inc · Solid Tumor Malignancies, Malignant Mesothelioma (MM)
- VTRU200Phase 21 trial
Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.